Sourek J, Oravec C, Männel D S
Institute of Hygiene and Epidemiology, Prague, Czechoslovakia.
Folia Microbiol (Praha). 1992;37(6):450-4. doi: 10.1007/BF02899904.
Natural and modified preparations of lipopolysaccharides and lipopolysaccharide-protein complexes isolated from the S- and R-form of Shigella dysenteriae serovar 1 were found to markedly inhibit the initial growth of mouse solid tumors derived from Németh-Kellner lymphoma, Gardner 6C3HED lymphoma, an ill-defined syngeneic lymphoma of DBA mice (Skalsky lymphoma) and LP-2 plasmacytoma. The biopreparations were given intraperitoneally, most frequently at a dose range from 50 to 200 micrograms per mouse; significant inhibitory effects on tumor growth were evidenced even in mice bearing tumors weighing 113 to 507 mg.
从痢疾志贺氏菌1型的S型和R型分离出的天然和改性脂多糖及脂多糖-蛋白质复合物制剂，被发现能显著抑制源自内梅特-凯尔纳淋巴瘤、加德纳6C3HED淋巴瘤、DBA小鼠的一种未明确的同基因淋巴瘤（斯卡尔斯基淋巴瘤）和LP-2浆细胞瘤的小鼠实体瘤的初始生长。生物制剂通过腹腔注射给药，最常用的剂量范围是每只小鼠50至200微克；即使在患有重量为113至507毫克肿瘤的小鼠中，也证明了对肿瘤生长有显著的抑制作用。
